Salirasib
| Title | Journal |
|---|---|
| PKA/CREB and NF-κB pathway regulates AKNA transcription: A novel insight into T-2 toxin-induced inflammation and GH deficiency in GH3 cells. | Toxicology 20171201 |
| Integrated Transcriptional and Proteomic Analysis of Growth Hormone Suppression Mediated by Trichothecene T-2 Toxin in Rat GH3 Cells. | Toxicological sciences : an official journal of the Society of Toxicology 20151001 |
| Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. | Investigational new drugs 20121201 |
| Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production. | Inflammation 20121001 |
| Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling. | International journal of cardiology 20120628 |
| Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. | Oncotarget 20120601 |
| Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells. | Biochemical and biophysical research communications 20120504 |
| Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120501 |
| Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. | International journal of cancer 20120315 |
| FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. | Cell death & disease 20120301 |
| Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid. | Digestive diseases and sciences 20120201 |
| Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. | Oncotarget 20120201 |
| Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release. | Inflammation 20111001 |
| Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor. | The Journal of investigative dermatology 20111001 |
| Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. | Molecular cancer therapeutics 20110801 |
| A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801 |
| ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. | Biochemical and biophysical research communications 20110617 |
| Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. | Journal of medicinal chemistry 20110512 |
| Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. | Acta gastro-enterologica Belgica 20110301 |
| Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. | International journal of cancer 20110201 |
| Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro. | Journal of pharmaceutical sciences 20110101 |
| The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. | PloS one 20110101 |
| Ras inhibition induces insulin sensitivity and glucose uptake. | PloS one 20110101 |
| The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. | Journal of neuroimmunology 20101215 |
| Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. | Biophysical journal 20101117 |
| Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase. | Cell research 20100801 |
| Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. | Molecular cancer therapeutics 20100801 |
| Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. | Journal of medicinal chemistry 20100722 |
| Dynamic changes in the TRPA1 selectivity filter lead to progressive but reversible pore dilation. | American journal of physiology. Cell physiology 20100601 |
| Salirasib in the treatment of pancreatic cancer. | Future oncology (London, England) 20100601 |
| Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. | International journal of cancer 20100515 |
| Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. | Bioorganic & medicinal chemistry 20100515 |
| Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. | Oncogene 20100121 |
| The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat. | Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20100101 |
| Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. | Cancer chemotherapy and pharmacology 20100101 |
| Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. | Molecular cancer 20100101 |
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. | Nature chemical biology 20091001 |
| Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. | European journal of pharmacology 20090815 |
| The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. | European journal of cancer (Oxford, England : 1990) 20090701 |
| Novel farnesylthiosalicylate (FTS)-eluting composite structures. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628 |
| Ras inhibition attenuates myocardial ischemia-reperfusion injury. | Biochemical pharmacology 20090515 |
| New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. | Journal of medicinal chemistry 20090108 |
| Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. | Molecular cancer therapeutics 20081101 |
| Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. | Journal of leukocyte biology 20081001 |
| Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080615 |
| N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. | European journal of immunology 20080601 |
| The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. | Digestive diseases and sciences 20080401 |
| Activation of TRPA1 by farnesyl thiosalicylic acid. | Molecular pharmacology 20080401 |
| Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. | Clinical science (London, England : 1979) 20080101 |
| Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. | Cancer chemotherapy and pharmacology 20080101 |
| Inhibitors of chronically active ras: potential for treatment of human malignancies. | Recent patents on anti-cancer drug discovery 20080101 |
| The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. | Methods in enzymology 20080101 |
| Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion. | Cancer research 20070815 |
| Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats. | Journal of neurotrauma 20070801 |
| Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). | Molecular cancer therapeutics 20070601 |
| The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. | Cell death and differentiation 20070501 |
| Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). | Cancer research 20070401 |
| Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells. | Pharmacology 20070101 |
| Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. | The Journal of steroid biochemistry and molecular biology 20070101 |
| The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060915 |
| Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. | Molecular cancer therapeutics 20060901 |
| Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. | Biochemical pharmacology 20060814 |
| E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. | International journal of cancer 20060801 |
| Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells. | Cell death and differentiation 20060401 |
| Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. | Anti-cancer drugs 20060101 |
| Hitting Ras where it counts: Ras antagonism in the basolateral amygdala inhibits long-term fear memory. | The European journal of neuroscience 20060101 |
| Using inhibitors of prenylation to block localization and transforming activity. | Methods in enzymology 20060101 |
| Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. | International journal of cancer 20051210 |
| Inhibition of Ras attenuates the course of experimental autoimmune neuritis. | Journal of neuroimmunology 20051101 |
| The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. | Kidney international 20050801 |
| Getting at MYC through RAS. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. | Cancer research 20050201 |
| Hydrogen peroxide-induced extracellular signal-regulated kinase activation in cultured feline ileal smooth muscle cells. | The Journal of pharmacology and experimental therapeutics 20050101 |
| Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. | Molecular endocrinology (Baltimore, Md.) 20050101 |
| Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. | Journal of the American Society of Nephrology : JASN 20050101 |
| Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. | Immunobiology 20050101 |
| The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. | Journal of neurochemistry 20040801 |
| Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. | Journal of hepatology 20040801 |
| The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. | The Prostate 20040301 |
| Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor. | Cell death and differentiation 20040201 |
| Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. | Arteriosclerosis, thrombosis, and vascular biology 20040201 |
| Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. | The Biochemical journal 20031201 |
| Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. | International journal of cancer 20030610 |
| New approaches to the understanding of tamoxifen action and resistance. | Endocrine-related cancer 20030601 |
| The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20030601 |
| Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. | Journal of the American Society of Nephrology : JASN 20030401 |
| Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. | The Journal of investigative dermatology 20030101 |
| Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. | Immunobiology 20030101 |
| Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. | Circulation 20020521 |
| Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. | International journal of cancer 20020401 |
| The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020201 |
| Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). | Clinical and experimental immunology 20011201 |
| The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. | Journal of neuroimmunology 20011101 |
| Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. | The Journal of biological chemistry 20010615 |
| Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. | Pharmacology, biochemistry, and behavior 20000801 |
| Dislodgment and accelerated degradation of Ras. | Biochemistry 19980203 |